Report cover image

GLP-1R Agonists – Label Extensions/Drug Repurposing: Market Overview

Publisher GlobalData
Published Apr 29, 2025
Length 73 Pages
SKU # GBDT20028610

Description

GLP-1R Agonists – Label Extensions/Drug Repurposing: Market Overview

Summary

This report is a market overview of GLP-1R agonists, focusing on their potential repurposing and label expansions in diseases outside type 2 diabetes and obesity.

The potential of GLP-1RAs is based on their insulin sensitization and anti-inflammatory properties.

GLP-1RAs are being investigated in different diseases in the metabolic, neurologic, and cardiologic markets.

Novo Nordisk and Eli Lilly are currently the major players in the GLP-1RA space, but opportunity remains for new entrants.

Scope
  • Overview of GLP-1R agonists, including marketed GLP-1RAs and diseases under investigation.
  • Analysis of unmet needs, challenges and opportunities in GLP-1RAs repurposing.
  • Pipeline analysis and opportunity assessment of GLP-1RAs in different therapeutic areas.
  • Overview of current major players in the GLP-1RAs space and potential future players.
  • GLP-1RAs global market outlook and deals overview.
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the GLP-1RAs therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GLP-1RAs therapeutics market in the future.
  • Identify the major challenges and opportunities in the GLP-1RA space and the potential of this therapeutic class in multiple indications.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

73 Pages
1 Preface
1.1 Contents
1.2 Abbreviations
1.3 Related Reports
2 Executive Summary
3 GLP-1R Agonists Overview
3.1 What Are GLP-1R Agonists
3.2 GLP-1R in the Body
3.3 History of GLP-1R Agonists
4 Industry Trends
4.1 Oral GLP-1Ras
4.2 Lower Dosing Frequency
4.3 Combination and Dual/Triple Agonists
4.4 Repurposing GLP-1Ras
5 Marketed Products
5.1 Global GLP-1RA Marketed Landscape
5.2 Marketed GLP-1Ras
5.3 Challenges and Opportunities in GLP-1RA Repurposing
5.4 Key Opinion Leader Perspectives on GLP-1RA Unmet Needs
6 Pricing and Reimbursement Assessment Case Study: Ozempic
7 Pipeline Analysis
7.1 Top 20 Indications with GLP-1RAs in Development
7.2 Top Five Therapeutic Areas with the Most GLP-1RA Pipeline Assets
7.3 GLP-1RA Pipeline Candidates
7.4 Where Are GLP-1RAs Expected to Position in the Future Chronic Kidney Disease Treatment Landscape?
7.5 Where Are GLP-1RAs Expected to Position in the Future Heart Failure Treatment Landscape?
7.6 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment for Heart Failure and Chronic Kidney Disease
7.7 GLP-1RA Opportunities Beyond Planned Label Expansions
7.8 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Polycystic Ovary Syndrome
8 Opportunities and Challenges
8.1 Opportunities: the Role of GLP-1RAs in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
8.2 Opportunities: GLP-1RAs in Liver Diseases
8.3 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Liver Diseases
8.4 Opportunities: the Role of GLP-1RAs in Neurodegenerative Diseases
8.5 Opportunities: GLP-1RAs in Central Nervous System Disorders
8.6 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Parkinson’s Disease
8.7 Opportunities: the Role of GLP-1RAs in Diastolic Heart Failure and Stroke
8.8 Opportunities: GLP-1RAs in Cardiovascular Diseases
8.9 Opportunities: the Role of GLP-1RAs in Chronic Kidney Disease
8.10 Opportunities: GLP-1RAs in Other Diseases
9 Companies
9.1 Current Major Player: Novo Nordisk
9.2 Current Major Player: Eli Lilly
9.3 Potential Future Players
9.4 Key Opinion Leader Perspectives on Future Players in the GLP-1RA Space
10 Market Outlook and Deals
10.1 GLP-1RA Global Market
10.2 Top 20 Major Deals and Acquisitions Between 2022 and 2025 with GLP-1Ras
11 Appendix
11.1 Bibliography
11.2 Primary Research – KOL Information
11.3 About the Authors
12 Contact Us

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us